Dietmar Lohmann Selected Research

Retinoblastoma (Glioblastoma, Retinal)

4/2022	RB1-Negative Retinal Organoids Display Proliferation of Cone Photoreceptors and Loss of Retinal Differentiation.
1/2022	TFF1 in Aqueous Humor-A Potential New Biomarker for Retinoblastoma.
1/2022	Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma.
4/2020	Corrigendum to "Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity"" [Prog. Retina Eye Res. 73 (2019) 100764].
11/2019	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity".
1/2018	The Interdisciplinary Diagnosis and Treatment of Intraocular Tumors.
7/2015	Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre.
10/2013	Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
4/2013	Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dietmar Lohmann Research Topics

Disease

9	Retinoblastoma (Glioblastoma, Retinal) 04/2022 - 04/2013
5	Neoplasms (Cancer) 04/2022 - 04/2013
3	Neoplasm Metastasis (Metastasis) 11/2019 - 04/2013
1	Carcinogenesis 01/2020
1	Pinealoma (Pineoblastoma) 01/2020
1	Margins of Excision 07/2015
1	Hyperthermia 10/2013
1	Peutz-Jeghers Syndrome (Polyposis, Hamartomatous Intestinal) 05/2013
1	Uveal melanoma 04/2013
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2010

Drug/Important Bio-Agent (IBA)

2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 10/2013
2	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 10/2013
2	Proteins (Proteins, Gene)FDA Link 05/2013 - 04/2013
1	Retinaldehyde (Retinal)IBA 04/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Etoposide (VP 16)FDA LinkGeneric 01/2022
1	Vincristine (Oncovin)FDA LinkGeneric 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2020
1	antineoplaston A10 (A 10)IBA 07/2015
1	Nonsense Codon (Nonsense Mutation)IBA 05/2013
1	Circulating Tumor DNAIBA 04/2013
1	DNA (Deoxyribonucleic Acid)IBA 04/2013
1	Cell-Free Nucleic AcidsIBA 04/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2010

Therapy/Procedure

4	Therapeutics 01/2022 - 10/2013
3	Drug Therapy (Chemotherapy) 01/2022 - 07/2015
3	Conservative Treatment 04/2020 - 10/2013
2	Brachytherapy 01/2018 - 10/2013
1	Vitrectomy 07/2015
1	Radiotherapy 07/2015
1	Adjuvant Chemotherapy 07/2015
1	Cryotherapy (Therapy, Cold) 10/2013
1	Laser Coagulation 10/2013
1	Long-Term Care 04/2013